ArticleBritish journal of cancer2015
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Proceedings of the National Academy of Sciences of the United States of America · 2015Trial
- A 13-gene prognostic model developed using machine learning to predict the response to neoadjuvant chemoradiotherapy in rectal carcinoma.Cancer cell international · 2026Article
- Kinesin Family Member 26A Disrupts DNA-Dependent Protein Kinase Complex Formation to Enhance Chemoradiotherapy Sensitivity in Colorectal Cancer.International journal of biological sciences · 2026Article
- Cancer Immunotherapies: Navigating the Immune Landscape.Current cancer drug targets · 2026Review
- Pan-cancer landscape of cellular senescence heterogeneity reveals associations with prognosis and therapy response.Scientific reports · 2025Article
- Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Article
- Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics.Journal of translational medicine · 2023Article
- Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Med (New York, N.Y.) · 2023Article
- Synaptophysin-like 2 expression correlates with lymph node metastasis and poor prognosis in colorectal cancer patients.World journal of gastrointestinal oncology · 2022Article
- Article
- PRMT5 promotes colorectal cancer growth by interaction with MCM7.Journal of cellular and molecular medicine · 2021Article
- Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.Frontiers in immunology · 2020Review
- An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer.Journal of extracellular vesicles · 2019Article
- Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.The Journal of pathology · 2018Article
- Bloch surface wave enhanced biosensor for the direct detection of Angiopoietin-2 tumor biomarker in human plasma.Biomedical optics express · 2018Article
- Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.PloS one · 2018Article
- The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Angiogenesis · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study characterises molecular effect of bevacizumab, and explores the relation of molecular and genetic markers with response to bevacizumab combined with chemoradiotherapy (CRT).
methodsFrom a subset of 59 patients of 84 rectal cancer patients included in a phase II study combining bevacizumab with CRT, tumour and blood samples were collected before and during treatment, offering the possibility to evaluate changes induced by one dose of bevacizumab. We performed cDNA microarrays, stains for CD31/CD34 combined with α-SMA and CA-IX, as well as enzyme-linked immunosorbent assay (ELISA) for circulating angiogenic proteins. Markers were related with the pathological response of patients.
resultsOne dose of bevacizumab changed the expression of 14 genes and led to a significant decrease in microvessel density and in the proportion of pericyte-covered blood vessels, and a small but nonsignificant increase in hypoxia. Alterations in angiogenic processes after bevacizumab delivery were only detected in responding tumours. Lower PDGFA expression and PDGF-BB levels, less pericyte-covered blood vessels and higher CA-IX expression were found after bevacizumab treatment only in patients with pathological complete response.
conclusionsWe could not support the 'normalization hypothesis' and suggest a role for PDGFA, PDGF-BB, CA-IX and α-SMA. Validation in larger patient groups is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.